Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401937 | 1.00 | NPSR1 (0.52) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL19968923 | 1.00 | NPSR1 (0.52) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL11373534 | 0.83 | HCAR2 (0.47) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL11373532 | 0.83 | HCAR2 (0.47) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL9512735 | 0.82 | NPSR1 (0.56) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL2952591 | 0.82 | NPSR1 (0.56) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL2948325 | 0.82 | NPSR1 (0.56) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL17679347 | 0.80 | NPSR1 (0.46) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL18290046 | 0.80 | NPSR1 (0.54) | NPSR1ALDH1A1TRPA1HCAR2LMNA | |
| SCHEMBL4424904 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2703407-B1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | KOWA CO (JP) | 2017-07-26 | — | — | EP | claimed |
| US-9540301-B2 | Method for manufacturing phosphonocrotonic acid derivative | KOWA COMPANY, LTD. (JP) | 2017-01-10 | — | — | US | claimed |
| EP-2703407-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | Kowa Company, Ltd. (JP) | 2014-03-05 | — | — | EP | claimed |
| US-20140051876-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | MANAC INCORPORATED (JP) | 2014-02-20 | — | — | US | claimed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| CN-113710667-A | Fused cyclic pyrimidinone derivatives for the treatment of HBV infection or HBV induced diseases | 爱尔兰詹森科学公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20190047933-A1 | PROCESS FOR THE SYNTHESIS OF (2E, 4E, 6Z, 8E)-8-(3,4-DIHYDRONAPHTHALEN-1(2H)-YLIDENE)-3,7-DIMETHYLOCTA-2, 4, 6-TRIENOIC ACID | BRICKELL BIOTECH, INC. | 2019-02-14 | — | — | US | disclosed |
| US-4661617-A | PESTICIDES | SANDOZ LTD. (CH) | 1987-04-28 | — | — | US | disclosed |
| US-4172146-A | Substituted phenyl derivatives | CIBA-GEIGY CORPORATION (US) | 1979-10-23 | — | — | US | disclosed |
| US-4097496-A | ANTIPROSTAGLANDIN ACTIVITY | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-27 | — | — | US | disclosed |
| US-4083990-A | ANTIPROSTAGLANDIN EFFECT | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-04-11 | — | — | US | disclosed |
| US-4069344-A | INSECTICIDAL SUBSTITUTED PHENYL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-3984459-A | ANTI-PROSTAGLANDINS | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-10-05 | — | — | US | disclosed |
| US-3984455-A | Prostaglandin E1 analogs | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3978100-A | Allenic esters, process for preparation thereof and process for rearrangement thereof | KURARAY CO., LTD. (JA) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | NPSR1 3514/4885ALDH1A1 1508/4885TRPA1 4864/4885 |
| US-20140051876-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | C1S, C3AR1, C9 | NPSR1 1590/4885ALDH1A1 1492/4885TRPA1 4433/4885 |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | NPSR1 3917/4885ALDH1A1 2607/4885TRPA1 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.